News
Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)
OBI Pharma (‘OBI’, TPEx: 4174) has signed a licensing agreement and a master services and clinical supply agreement with Abzena plc (AIM: ABZA, ‘Abzena’ or …
OBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals
OBI Pharma to develop OBI-3424 (previously TH-3424) as a potential treatment of cancers expressing AKR1C3. Taipei, Taiwan, June 1, 2017 — OBI Pharma, Inc., a …
China FDA approves Clinical Trial Application for Adagloxad Simolenin Phase III Study
On 24 January 2017, OBI Pharma, Inc. (4174) received formal approval from the China Food and Drug Administration (CFDA) to conduct a proposed phase III …
OBI Pharma holds EOP2 meeting with US FDA
OBI Pharma, Inc. has met with the Office of Tissues and Advanced Therapies (OTAT) of the US Food and Drug Administration (FDA) for its End-of-Phase …
OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence.
OBI Pharma Deeply Disappointed with Prosecutor’s Decision to Proceed with Cases. Facts should demonstrate Innocence. Shi-Lin District prosecutors Office announced today (9 Jan 2017) the …